These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22551544)

  • 1. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
    Dettmar K; Seitz-Merwald I; Lindemann C; Schroeder P; Seimetz D; Atz J
    Clin Transl Oncol; 2012 May; 14(5):376-81. PubMed ID: 22551544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
    Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
    Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
    Hirschhaeuser F; Walenta S; Mueller-Klieser W
    Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
    Riechelmann H; Wiesneth M; Schauwecker P; Reinhardt P; Gronau S; Schmitt A; Schroen C; Atz J; Schmitt M
    Cancer Immunol Immunother; 2007 Sep; 56(9):1397-406. PubMed ID: 17273869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
    Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
    Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
    MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
    Riesenberg R; Buchner A; Pohla H; Lindhofer H
    J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA
    Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
    Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
    Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
    J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.
    Wulf-Goldenberg A; Eckert K; Fichtner I
    Cytotherapy; 2011 Jan; 13(1):108-13. PubMed ID: 20839999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
    Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
    Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent immunomodulatory effects of the trifunctional antibody catumaxomab.
    Goéré D; Flament C; Rusakiewicz S; Poirier-Colame V; Kepp O; Martins I; Pesquet J; Eggermont A; Elias D; Chaput N; Zitvogel L
    Cancer Res; 2013 Aug; 73(15):4663-73. PubMed ID: 23737485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.